Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth O'Donnell

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpThomas Martin, Saad Z Usmani, Jesus G Berdeja, et al.
Blood Advances|June 5, 2025
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemiaAndrew R Branagan, Clifton Mo, Matthew Lei, et al.
Blood Cancer Discovery|March 5, 2024
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple MyelomaIrene M Ghobrial, Nicole Gormley, Shaji K Kumar, et al.
Lancet (London, England)|June 27, 2021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyJesus G Berdeja, Deepu Madduri, Saad Z Usmani, et al.
The Lancet. Haematology|February 3, 2022
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working GroupNoopur S Raje, Elias Anaissie, Shaji K Kumar, et al.
Nature Medicine|April 20, 2026
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trialOmar Nadeem, David M Cordas Dos Santos, Sarah Nikiforow, et al.
Research Square|June 12, 2025
Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0)Floris Chabrun, Daniel Schwartz, Susanna Gentile, et al.
JHEP Reports : Innovation in Hepatology|March 8, 2021
Real-world experience with obeticholic acid in patients with primary biliary cholangitisDaphne D'Amato, Antonio De Vincentis, Federica Malinverno, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpThomas Martin, Saad Z Usmani, Jesus G Berdeja, et al.
Blood Advances|June 5, 2025
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemiaAndrew R Branagan, Clifton Mo, Matthew Lei, et al.
Blood Cancer Discovery|March 5, 2024
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple MyelomaIrene M Ghobrial, Nicole Gormley, Shaji K Kumar, et al.
Lancet (London, England)|June 27, 2021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyJesus G Berdeja, Deepu Madduri, Saad Z Usmani, et al.
The Lancet. Haematology|February 3, 2022
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working GroupNoopur S Raje, Elias Anaissie, Shaji K Kumar, et al.
Nature Medicine|April 20, 2026
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trialOmar Nadeem, David M Cordas Dos Santos, Sarah Nikiforow, et al.
Research Square|June 12, 2025
Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0)Floris Chabrun, Daniel Schwartz, Susanna Gentile, et al.
JHEP Reports : Innovation in Hepatology|March 8, 2021
Real-world experience with obeticholic acid in patients with primary biliary cholangitisDaphne D'Amato, Antonio De Vincentis, Federica Malinverno, et al.
Pageof 5